Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent mucosal infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. They are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens including Covid. Lactiga has earned multiple awards, media attention (Globe & Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.
AngelMD Profile: https://www.angelmd.co/en/startups/lactiga
DelNova, Inc. is a biopharmaceutical company focused on addressing unmet medical needs. DelNova is resolving complications arising from botulinum toxin therapies (eg. Botox®). The...
Clint McGill is addressing one of the biggest challenge in youth sports - building mental toughness. As a former high level baseball player himself,...
In this episode, host Tobin Arthur is joined by colleagues Katie Richardson, MD and Mike Schmanske interviewing startup Founder Kate Dilligan of Cooler Heads....
